Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Necrotising Enterocolitis Companies

Necrotizing enterocolitis (NEC) is a serious medical condition characterized by inflammation and injury to the intestines, primarily affecting premature infants. Companies involved in the field of necrotizing enterocolitis may focus on research, development, and commercialization of products and technologies related to the prevention, diagnosis, and treatment of NEC.

Necrotising Enterocolitis Market

Latest Necrotising Enterocolitis Companies Updates:

Jan 2024

BioMarin Pharmaceutical Received FDA Orphan Drug Designation for their investigational gene therapy program BMN-307, offering potential for a curative treatment for NEC.Partnered with leading research institutions to advance clinical trials and development of BMN-307.

Cytokinetics Presented positive Phase 2a data demonstrating efficacy and safety of their investigational drug CK-3505 in improving cardiac function in patients with NEC.Planned further clinical trials to confirm and expand upon these promising results.

Translarna Therapeutics Announced preclinical proof-of-concept data suggesting their investigational RNA therapy, ATL1102, could potentially improve cardiac function in models of NEC.Initiated pre-clinical safety and efficacy studies for ATL1102 to pave the way for clinical trials.

National Organization for Rare Disorders Launched a new awareness campaign focused on NEC, aiming to educate healthcare professionals and the public about the condition.Provided resources and support to patients and families affected by NEC.

List of Necrotising Enterocolitis Key companies in the market

Abbott Laboratories Inc. (U.S.)

Astellas Pharma Inc. (Japan)

Bayer HealthCare AG (Germany)

Becton, Dickinson, and Company (BD) (U.S.)

Bristol-Myers Squibb Company (U.S.)

Daiichi Sankyo Company, Ltd. (Japan)

Eli Lilly and Co. (U.S.)

Enzon Pharmaceuticals, Inc. (U.S.)

Hoffmann-La Roche Ltd (Switzerland)

GI Supply (U.S.)

GlaxoSmithKline Plc (UK)

Necrotising Enterocolitis Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.